This section highlights FDA-related milestones and regulatory updates for drugs developed by AbCellera Biologics (ABCL).
Over the past two years, AbCellera Biologics has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as
ABCL635 and ABCL575. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend.
Select a button below to view the list of FDA events for that drug.
ABCL635 FDA Regulatory Timeline and Events
ABCL635 is a drug developed by AbCellera Biologics for the following indication: For Vasomotor Symptoms Due to Menopause.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- ABCL635
- Announced Date:
- September 17, 2026
- Indication:
- For Vasomotor Symptoms Due to Menopause
Announcement
AbCellera announced an upcoming oral presentation of Phase 2 data on ABCL635 at the International Menopause Society (IMS) 20th World Congress on Menopause, to be held September 30 to October 3, 2026 at the Windsor Oceânico Hotel and Congress Center in Rio de Janeiro, Brazil.
AI Summary
AbCellera plans to present interim Phase 1/2 results for ABCL635 at the International Menopause Society’s 20th World Congress on Menopause in Rio de Janeiro, Brazil. The congress runs September 30 to October 3, 2026, at the Windsor Oceânico Hotel and Congress Center.
The oral presentation, titled “Interim Results of a Phase 1/2 Study of ABCL635, a First-in-Class NK3R Monoclonal Antibody for the Treatment of Vasomotor Symptoms,” is scheduled for Thursday, October 1, from 8:30 to 9:30 a.m. local time. It will take place in the “Symptoms of Menopause 1” session in Aruba 1. AbCellera will share safety and efficacy data from a Phase 2 trial involving postmenopausal women with moderate-to-severe vasomotor symptoms, including hot flashes and night sweats.
ABCL635 is an investigational, non-hormonal antibody designed to target NK3R. The company is studying it as a long-acting treatment for these symptoms.
Read Announcement- Drug:
- ABCL635
- Announced Date:
- August 10, 2026
- Indication:
- For Vasomotor Symptoms Due to Menopause
Announcement
AbCellera announced positive top-line results from the Phase 2 portion of its Phase 1/2 clinical trial evaluating ABCL635, an investigational neurokinin 3 receptor (NK3R) antagonist antibody. ABCL635 is being developed as a non-hormonal, long-acting, subcutaneous treatment for moderate-to-severe vasomotor symptoms (VMSM-S), commonly known as hot flashes, due to menopause.
AI Summary
AbCellera reported positive Phase 2 results for ABCL635, an investigational antibody being developed as a non-hormonal, long-acting injection for moderate-to-severe menopause-related hot flashes. In a four-week study of 92 postmenopausal women, one 600 mg dose reduced hot-flash frequency and severity significantly more than placebo. At week four, participants receiving ABCL635 had an average of 8.8 fewer hot flashes per day, compared with 3.5 fewer for placebo. Hot-flash severity also fell more with treatment. The company described the reductions as potentially best-in-class.
Participants also reported improved sleep and a better overall impression of their condition. ABCL635 was generally well tolerated, with no serious or severe adverse events and no treatment-related withdrawals. Headache, fatigue, and injection-site reactions were more common than with placebo. The results are from an early-stage trial, and further studies are needed to confirm the treatment’s benefits and risks. AbCellera says ABCL635 could offer a convenient option for women seeking relief from disruptive menopausal symptoms.
Read Announcement- Drug:
- ABCL635
- Announced Date:
- August 7, 2026
- Target Action Date:
- August 10, 2026
- Indication:
- For Vasomotor Symptoms Due to Menopause
Announcement
AbCellera will release top-line data from its Phase 2 trial evaluating ABCL635 for the treatment of moderate-to-severe vasomotor symptoms (VMS) due to menopause before the market opens on Monday, August 10, 2026 and hold an investor conference call at 4:30 a.m. Pacific Time (7:30 a.m. Eastern Time) the same day.
AI Summary
AbCellera will announce top-line results from its Phase 2 trial of ABCL635 before the U.S. stock market opens on Monday, August 10, 2026. The company will host an investor conference call that day at 4:30 a.m. Pacific Time (7:30 a.m. Eastern Time). A live webcast link and a later replay will be available on AbCellera’s Investor Relations website.
ABCL635 is an investigational, non-hormonal antibody treatment for moderate-to-severe vasomotor symptoms (VMS), including menopause-related hot flashes. It targets NK3R, a receptor found on brain cells involved in regulating body temperature. The randomized, double-blind, placebo-controlled Phase 2 study is testing whether the drug can reduce the frequency and severity of VMS. It includes about 80 postmenopausal women. The trial’s results will provide an early look at the treatment’s potential; the company has not yet announced the findings.
Read Announcement- Drug:
- ABCL635
- Announced Date:
- January 12, 2026
- Indication:
- For Vasomotor Symptoms Due to Menopause
Announcement
AbCellera announced that the first patients have been dosed in the Phase 2 portion of its ongoing Phase 1/2 clinical trial for ABCL635. ABCL635 is a potential first-in-class non-hormonal treatment for moderate-to-severe vasomotor symptoms (VMS) associated with menopause.
AI Summary
AbCellera announced that the first patients have been dosed in the Phase 2 portion of its ongoing Phase 1/2 trial of ABCL635, a potential first-in-class non-hormonal treatment for moderate-to-severe vasomotor symptoms (VMS) of menopause.
The move into Phase 2 follows an interim review of safety, tolerability and pharmacodynamic data from Phase 1. The Phase 2 study is multicenter, randomized, double-blind and placebo-controlled, and will test whether ABCL635 reduces the frequency and severity of VMS in about 80 postmenopausal women.
AbCellera’s chief medical officer said encouraging Phase 1 safety and target-engagement data, along with a strong mechanistic rationale, supported advancing to randomized testing. The company aims to evaluate ABCL635 as a safe, effective non-hormonal option for women seeking symptom relief.
The company designated the trial as Phase 1/2 with a randomized proof-of-concept part and expects top-line results in Q3 2026. ABCL635 targets the NK3R receptor on KNDy neurons.
Read Announcement- Drug:
- ABCL635
- Announced Date:
- May 14, 2025
- Target Action Date:
- Q3 2025
- Estimated Target Date Range:
- July 1, 2025 - September 30, 2025
- Indication:
- For Vasomotor Symptoms Due to Menopause
Announcement
AbCellera announced that it anticipates starting the Phase 1 clinical trial for ABCL635 in Q3 2025
AI Summary
AbCellera announced that it expects to start the Phase 1 clinical trial for its investigational drug ABCL635 in the third quarter of 2025. ABCL635 is developed as a non-hormonal treatment for moderate-to-severe vasomotor symptoms, which are hot flashes experienced during menopause. The upcoming Phase 1 trial will focus on testing the safety of the drug along with its pharmacokinetics and pharmacodynamics. The study will involve both healthy volunteers and postmenopausal women who experience these disruptive symptoms. This trial is an important step for AbCellera as it works to develop a long-acting treatment option that could help millions of women manage menopause-related symptoms. The initiation of the Phase 1 trial marks a significant milestone in advancing ABCL635 through the clinical development process.
Read Announcement- Drug:
- ABCL635
- Announced Date:
- May 14, 2025
- Indication:
- For Vasomotor Symptoms Due to Menopause
Announcement
AbCelleraannounced it has received a No Objection Letter (NOL) from Health Canada authorizing its Clinical Trial Application (CTA) for ABCL635, an investigational antibody antagonist targeting neurokinin 3 receptor (NK3R) that is being developed for the non-hormonal treatment of moderate-to-severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause.
AI Summary
AbCellera announced that it has received a No Objection Letter (NOL) from Health Canada, which approves its Clinical Trial Application (CTA) for the investigational drug ABCL635. This antibody antagonist targets the neurokinin 3 receptor (NK3R) and is being developed as a non-hormonal treatment approach for moderate-to-severe vasomotor symptoms (VMS), commonly known as hot flashes, experienced during menopause.
The NOL allows AbCellera to advance ABCL635 into Phase 1 clinical trials, which are planned to begin in Q3 2025. During these trials, the company will evaluate the safety, pharmacokinetics, and pharmacodynamics of ABCL635 in both healthy participants and postmenopausal women. AbCellera hopes that this new treatment will provide a long-acting and effective solution to ease the disruptive symptoms of menopause, ultimately improving the quality of life for many women.
Read Announcement
ABCL575 FDA Regulatory Events
ABCL575 is a drug developed by AbCellera Biologics for the following indication: For the treatment of moderate-to-severe atopic dermatitis (AD).
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- ABCL575
- Announced Date:
- August 27, 2025
- Indication:
- For the treatment of moderate-to-severe atopic dermatitis (AD)
Announcement
AbCellera announced it has dosed the first participants in its Phase 1 clinical trial of ABCL575, a next-generation investigational antibody therapy being developed for the treatment of moderate-to-severe atopic dermatitis (AD), with potential applications for other inflammatory and autoimmune conditions.
AI Summary
AbCellera announced it has dosed the first participants in its Phase 1 clinical trial of ABCL575, a next-generation investigational antibody therapy for moderate-to-severe atopic dermatitis (AD). The company plans to test safety and tolerability while exploring less frequent dosing to improve patient convenience.
ABCL575 is an Fc‐silenced, half‐life extended antibody designed to bind OX40 ligand (OX40L) and disrupt OX40/OX40L signaling, which regulates inflammatory pathways in AD. In preclinical studies, it showed strong inhibition of T cell–mediated inflammation and a favorable safety profile.
The Phase 1 trial (NCT07108894) is randomized, placebo‐controlled, and double‐blind. Healthy volunteers will receive subcutaneous doses of ABCL575 or placebo. The study’s main goal is to assess safety and tolerability after a single injection.
With an extended half‐life that may allow dosing every six months, ABCL575 could offer greater convenience than current therapies. AbCellera expects to share initial data by mid-2026 and is also exploring uses in other inflammatory and autoimmune conditions.
Read Announcement- Drug:
- ABCL575
- Announced Date:
- May 30, 2025
- Indication:
- For the treatment of moderate-to-severe atopic dermatitis (AD)
Announcement
AbCellera announced it has received a No Objection Letter (NOL) from Health Canada authorizing its Clinical Trial Application (CTA) for ABCL575, an investigational antibody antagonist targeting OX40 ligand (OX40L) that is being developed for the treatment of moderate-to-severe atopic dermatitis (AD), with potential applications to other inflammatory and autoimmune conditions.
AI Summary
AbCellera Biologics Inc. announced that it has received a No Objection Letter (NOL) from Health Canada for its Clinical Trial Application (CTA) for ABCL575. This investigational antibody antagonist targets the OX40 ligand (OX40L), which plays a key role in inflammatory pathways related to moderate-to-severe atopic dermatitis (AD). The company is developing ABCL575 with the hope that it may benefit patients not only with AD, but also with other inflammatory and autoimmune conditions. The therapy has been engineered for an extended half-life and designed with an Fc-silenced modification for improved safety. AbCellera plans to begin a Phase 1 clinical trial in Q3 2025 to study the safety and pharmacokinetics of this treatment when administered subcutaneously in healthy participants.
Read Announcement